

Last trading day of non-voting equity securities (*Genussscheine*) and first trading day of participation certificates (*Partizipationsscheine*) at SIX Swiss Exchange

- **Roche's existing non-voting equity securities, *Genussscheine* under the ticker symbol "ROG", will have their last trading day on the SIX Swiss Exchange today.**
- **All *Genussscheine* are 1:1 exchanged for participation certificates, which will commence trading under the new ticker symbol "ROP" on the SIX Swiss Exchange at 9:00 a.m. CET tomorrow, 17 March 2026.**
- **The 1:1 exchange of *Genussscheine* held as intermediated securities for participation certificates will be processed via the banking system and participation certificates are automatically credited to accounts of such holders.**
- **Participation certificates are economically equivalent to *Genussscheine* and have the same entitlements to dividends and liquidation proceeds as the bearer shares.**

Basel, 16 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its current non-voting equity securities, *Genussscheine*, will have their last trading day on the SIX Swiss Exchange today, 16 March 2026 (the "cum date" for the exchange). The first trading day of the participation certificates on the SIX Swiss Exchange will be tomorrow, 17 March 2026 (the "ex date" for the exchange). Participation certificates will commence trading on the SIX Swiss Exchange at 9:00 a.m. CET and carry a new International Securities Identification Number (CH1499059983), a new Valor (149.905.998) and a new ticker symbol ("ROP"), which are different from those previously used for *Genussscheine*.

For holders who hold their *Genussscheine* as intermediated securities, the transition from *Genussscheine* to participation certificates does not require any action. Participation certificates will be processed through the banking system and automatically credited to the account of such holders by their custodian bank. Under the T+2 settlement cycle of SIX Swiss Exchange, investors who buy *Genussscheine* and do not dispose of them on or before 16 March 2026 (the "cum date" for the exchange) and whose purchases have settled so that they are holders of record on the record date for the exchange on 18 March 2026 are expected to receive participation certificates as intermediated securities. Transactions in *Genussscheine* that remain pending, or orders which remain open, at the end of 16 March 2026 may need to be re-entered as of 17 March 2026 and may not be reflected in holdings as of the record date. For further information, investors should contact their custodian bank.

Holders of printed certificates representing Roche equity securities (“home custodians”) are urged to promptly submit their printed certificates, together with the remaining dividend vouchers (if any), to a depository bank for conversion into intermediated securities. This will ensure smooth future dividend payments to current home custodians and avoid a potential loss of dividend claims. Dividends will be forfeited if not claimed within five years.

For additional details on the exchange of *Genussscheine* for participation certificates, please refer to the [listing prospectus](#), the [information document](#) and consult the dedicated FAQ section available [here](#).

About Roche

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

Roche Investor Relations

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com